A niche medical device manufacturer focused on delivering advanced healthcare solutions to hospitals and ambulatory centers with consistent revenue generation despite modest profit margins.
The stock offers exposure to the resilient medical device sector with a clean balance sheet showing strong cash reserves relative to current liabilities. Positive revenue consistency over the past three years suggests mature product lines that can serve as a stable foundation for future innovation-driven growth. Attractive valuation metrics combined with potential for margin expansion through operational efficiencies make it an interesting speculative play for long-term holders.
Investors should avoid this stock due to the substantial retained earnings deficit of $68.4M which signals historical struggles to convert revenue into sustainable profits. The company's cash position is under pressure from heavy increases in inventory and receivables, raising concerns about liquidity if sales growth stalls or credit terms worsen. Limited market capitalization and OTC listing status increase volatility risks while the lack of consistent profit growth limits appeal for conservative income-focused investors.
ESCALON MEDICAL CORP develops and manufactures medical devices designed to improve patient outcomes and enhance healthcare delivery systems. The company primarily serves hospitals, ambulatory surgical centers, and outpatient facilities across North America with a focus on innovative diagnostic and therapeutic solutions. Operating as a specialized medical technology provider, the firm leverages its proprietary engineering capabilities to address critical needs in modern clinical environments.
Recent financial performance shows stabilization with revenue holding steady at $12M while net income recovered to positive territory in 2025 after a minor loss in 2024. However, operating cash flow was heavily impacted by a significant increase in inventory levels and accounts receivable, resulting in negative working capital changes that offset operational earnings. The company generated sufficient operating profit to cover its modest debt obligations but still requires external financing for growth initiatives.
The global medical device industry is experiencing steady double-digit growth driven by aging demographics and increasing demand for minimally invasive procedures. Regulatory frameworks continue to tighten, favoring companies with robust clinical trial data and established safety records, which benefits incumbents with proprietary technologies. Consolidation trends are accelerating as smaller players seek acquisition targets or strategic partnerships to access new distribution channels.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $12.2M | $12.0M | $12.0M |
| Cost of Revenue | $6.7M | $6.8M | $6.5M |
| Gross Profit | $5.5M | $5.1M | $5.5M |
| Operating Expenses | $5.0M | $5.3M | $5.4M |
| Operating Income | $478.5K | $-104.5K | $133.2K |
| R&D | $818.8K | $688.2K | $753.1K |
| G&A | $4.2M | $4.6M | $4.6M |
| D&A | $45.2K | $46.0K | $37.8K |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $21.8K | $20.8K | — |
| Interest Income | $128 | — | — |
| Pre-Tax Income | $478.5K | $-104.5K | $133.2K |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $478.5K | $-104.5K | $133.2K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $456.8K | $-125.3K | $105.5K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $456.8K | $-125.3K | $105.5K |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $4.6M | $4.4M | $4.6M |
| Cash & Equivalents | $889.7K | $209.0K | $545.8K |
| Accounts Receivable | $1.7M | $2.1M | $1.5M |
| Inventory | $1.6M | $1.6M | $2.1M |
| Other Current Assets | $506.1K | $450.5K | $420.9K |
| Long-Term Assets | $670.5K | $361.1K | $381.1K |
| PP&E (Net) | $34.1K | $48.9K | $34.6K |
| Operating Leases | $503.6K | $200.0K | $254.0K |
| Other LT Assets | $132.8K | $112.2K | $92.6K |
| Total Assets | $5.3M | $4.8M | $5.0M |
| Current Liabilities | $2.9M | $2.7M | $2.7M |
| Accounts Payable | $1.2M | $1.4M | $1.4M |
| Current Leases | $329.6K | $208.0K | $86.5K |
| Other Current Liab | $665.9K | $515.4K | $578.1K |
| Long-Term Liabilities | $520.0K | $279.4K | $392.7K |
| LT Operating Leases | $214.1K | $8.1K | $168.0K |
| Other LT Liab | $305.9K | $271.3K | $224.7K |
| Total Liabilities | $3.4M | $2.9M | $3.1M |
| Shareholders' Equity | $1.9M | $1.8M | $1.9M |
| Paid-In Capital | $69.7M | $69.7M | $69.7M |
| Retained Earnings | $-68.4M | $-68.5M | $-68.4M |
| Total L&E | $5.3M | $4.8M | $5.0M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $456.8K | $-125.3K | $105.5K |
| Non-Cash Adjustments | $-154.7K | $-513.0K | $542.1K |
| Working Capital Changes | $23.1K | $35.5K | $-266.9K |
| Cash from Operations | $325.1K | $-602.8K | $380.7K |
| Capital Expenditures | $6.7K | $40.3K | $3.9K |
| Cash from Investing | $-13.8K | $-40.3K | $-3.9K |
| Debt Repayments | $3.1K | $3.9K | $3.4K |
| Cash from Financing | $-15.4K | $-37.5K | $-39.9K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $295.9K | $-680.5K | $336.9K |
| Beginning Cash | $850.0K | $1.1M | $465.5K |
| Ending Cash | $1.1M | $465.5K | $802.4K |
The company's revenue is derived from the sale of specialized medical equipment, ongoing service contracts for device maintenance, and licensing of proprietary technology platforms to third-party healthcare providers. Additional streams include strategic partnerships for co-developing next-generation diagnostic tools and direct sales to large hospital systems seeking cost-effective operational improvements.
Significant volatility in net income driven by large changes in working capital, particularly inventory buildups and receivables collection periods that impacted cash flow dynamics recently. The company faces potential regulatory hurdles as medical device approval timelines can delay revenue recognition for new product launches. Dependence on a limited number of large hospital clients creates concentration risk if any major contracts are terminated or renegotiated. Persistent retained earnings deficits indicate historical profitability challenges that could limit internal funding capabilities for expansion.
The company benefits from proprietary intellectual property protecting its core device designs, creating a barrier to entry for competitors in specific niche therapeutic areas. Its established relationships with major healthcare networks provide predictable demand cycles, while its lean capital structure allows for flexible reinvestment into R&D without heavy debt burdens. Cost-efficient manufacturing processes enable competitive pricing while maintaining healthy gross profit margins above 45%.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.